1887
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.

Hematologic Complications of Tuberculosis

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
Buy this Microbiology Spectrum Article
Price Non-Member $15.00
  • Authors: Shyam S. Balepur1, David Schlossberg2
  • Editor: David Schlossberg5
  • VIEW AFFILIATIONS HIDE AFFILIATIONS
    Affiliations: 1: ABBCI, Division of Hematology & Oncology, Penn Medicine/Lancaster General Health, Lancaster, PA 17601; 2: Temple University School of Medicine; 3: University of Pennsylvania School of Medicine; 4: Philadelphia Department of Public Health, Philadelphia, PA 19140; 5: Philadelphia Health Department, Philadelphia, PA
  • Source: microbiolspec December 2016 vol. 4 no. 6 doi:10.1128/microbiolspec.TNMI7-0004-2016
  • Received 11 September 2016 Accepted 26 September 2016 Published 23 December 2016
  • Shyam S. Balepur, ssbalepu@lghealth.org
image of Hematologic Complications of Tuberculosis
    Preview this microbiology spectrum article:
    Zoom in
    Zoomout

    Hematologic Complications of Tuberculosis, Page 1 of 2

    | /docserver/preview/fulltext/microbiolspec/4/6/TNMI7-0004-2016-1.gif /docserver/preview/fulltext/microbiolspec/4/6/TNMI7-0004-2016-2.gif
  • Abstract:

    Tuberculosis (TB) affects the production and life span of all hematologic cellular components. In addition, plasma coagulation factors may be affected, resulting in sometimes life-threatening complications. Iron, folate, and vitamin B metabolism is derailed. The pharmacological agents used for TB therapy may also cause hematologic changes. There are some uncommon manifestations of TB in nontuberculous hematologic patients. There have been some exciting developments in the field of imaging to screen for TB, TB pathophysiology at the cellular level, and our understanding of immune response in TB. Advances have been made in pharmacologic therapeutic options, including discovery of new drugs in the fight against drug-resistant TB, bearing in mind their hematologic effects. This chapter reviews and updates known hematologic effects of TB and its therapy and some lesser known effects of TB in patients with nontuberculous hematologic conditions.

  • Citation: Balepur S, Schlossberg D. 2016. Hematologic Complications of Tuberculosis. Microbiol Spectrum 4(6):TNMI7-0004-2016. doi:10.1128/microbiolspec.TNMI7-0004-2016.

Key Concept Ranking

Immune Systems
0.5147992
Tumor Necrosis Factor alpha
0.4752727
0.5147992

References

1. Lee SW, Kang YA, Yoon YS, Um SW, Lee SM, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ. 2006. The prevalence and evolution of anemia associated with tuberculosis. J Korean Med Sci 21:1028–1032. [PubMed] [PubMed]
2. Olaniyi JA, Aken’Ova YA. 2003. Haematological profile of patients with pulmonary tuberculosis in Ibadan, Nigeria. Afr J Med Med Sci 32:239–242. [PubMed]
3. Singh KJ, Ahluwalia G, Sharma SK, Saxena R, Chaudhary VP, Anant M. 2001. Significance of haematological manifestations in patients with tuberculosis. J Assoc Physicians India 49:788, 790–794.
4. Yaranal PJ, Umashankar T, Harish SG. 2013. Hematological profile in pulmonary tuberculosis. Int J Health Rehabil Sci 2:50–55.
5. Douglas SW, Adamson JW. 1975. The anemia of chronic disorders: studies of marrow regulation and iron metabolism. Blood 45:55–65. [PubMed]
6. Boeser HP. 1974. Iron metabolism in inflammation and malignant disease, p 605–640. In Jacobs A, Worwood M (ed), Iron in Biochemistry and Medicine, II. Academic Press, London, England.
7. Ebrahim O, Folb PI, Robson SC, Jacobs P. 1995. Blunted erythropoietin response to anaemia in tuberculosis. Eur J Haematol 55:251–254. [PubMed]
8. Rodrigues PN, Gomes SS, Neves JV, Gomes-Pereira S, Correia-Neves M, Nunes-Alves C, Stolte J, Sanchez M, Appelberg R, Muckenthaler MU, Gomes MS. 2011. Mycobacteria-induced anaemia revisited: a molecular approach reveals the involvement of NRAMP1 and lipocalin-2, but not of hepcidin. Immunobiology 216:1127–1134. [PubMed]
9. Wessling-Resnick M. 2010. Iron homeostasis and the inflammatory response. Annu Rev Nutr 30:105–122. [PubMed]
10. O’Connor NJ, Hotfbrand AV. 1998. Anaemia in systemic disease, p 38. In Delamore IW, Liu Yin JA (ed), Haematologic Aspects of Systemic Disease. Bailliere Tindall, London, England.
11. Toosi TD, Shahi F, Afshari A, Roushan N, Kermanshahi M. 2008. Neuropathy caused by B12 deficiency in a patient with ileal tuberculosis: a case report. J Med Case Rep 2:90. [PubMed]
12. Das BS, Devi U, Mohan Rao C, Srivastava VK, Rath PK, Das BS. 2003. Effect of iron supplementation on mild to moderate anaemia in pulmonary tuberculosis. Br J Nutr 90:541–550. [PubMed]
13. Isanaka S, Mugusi F, Urassa W, Willett WC, Bosch RJ, Villamor E, Spiegelman D, Duggan C, Fawzi WW. 2012. Iron deficiency and anemia predict mortality in patients with tuberculosis. J Nutr 142:350–357. [PubMed]
14. Minchella PA, Donkor S, Owolabi O, Sutherland JS, McDermid JM. 2015. Complex anemia in tuberculosis: the need to consider causes and timing when designing interventions. Clin Infect Dis 60:764–772. [PubMed]
15. Nusbaum NJ. 1991. Concise review: genetic bases for sideroblastic anemia. Am J Hematol 37:41–44. [PubMed]
16. Kuo PH, Yang PC, Kuo SS, Luh KT. 2001. Severe immune hemolytic anemia in disseminated tuberculosis with response to antituberculosis therapy. Chest 119:1961–1963. [PubMed]
17. Nandennavar M, Cyriac S, Krishnakumar, Sagar T. 2011. Immune hemolytic anemia in a patient with tuberculous lymphadenitis. J Glob Infect Dis 3:89–91. [PubMed]
18. Murray HW. 1978. Transient autoimmune hemolytic anemia and pulmonary tuberculosis. N Engl J Med 299:488. [PubMed]
19. Khvitiya NG, Khechinashvili GN, Sabanadze S. 2004. Erythrocyte structure and function in fibrocavernous tuberculosis and tuberculous meningitis. Bull Exp Biol Med 138:613–615. [PubMed]
20. Viallard JF, Parrens M, Boiron JM, Texier J, Mercie P, Pellegrin JL. 2002. Reversible myelofibrosis induced by tuberculosis. Clin Infect Dis 34:1641–1643. [PubMed]
21. Laszlo J, Huang AT. 1990. Anemia associated with marrow infiltration, p 546–548. In Williams WJ, Beutler E, Erslev AJ, Lichtman MA (ed), Hematology, 4th ed. McGraw-Hill, New York, NY.
22. Andre J, Schwartz R, Dameshek W. 1961. Tuberculosis and myelosclerosis with myeloid metaplasia; report of three cases. JAMA 178:1169–1174. [PubMed]
23. Adamson JW, Ersley AJ. 1990. Aplastic anemia, p 158–174. In Williams WJ, Beutler E, Erslev AJ, Lichtman MA (ed), Hematology, 4th ed. McGraw-Hill, New York, NY.
24. Knox-Macaulay HH, Knox-Macaulay HM. 1992. Tuberculosis and the haemopoietic system. Baillieres Clin Haematol 5:101–129.
25. Paydas S, Ergin M, Baslamisli F, Yavuz S, Zorludemir S, Sahin B, Bolat FA. 2002. Bone marrow necrosis: clinicopathologic analysis of 20 cases and review of the literature. Am J Hematol 70:300–305. [PubMed]
26. Singh R, Singh MM, Lahiri VL, Mirchandani HM. 1987. Tuberculosis as a continuing cause of secondary amyloidosis in northern India. J Indian Med Assoc 85:328–332. [PubMed]
27. Sunga MN, Jr, Reyes CV, Zvetina J, Kim TW. 1989. Resolution of secondary amyloidosis 14 years after adequate chemotherapy for skeletal tuberculosis. South Med J 82:92–93. [PubMed]
28. Gallagher NI, Donati RM. 1968. Inappropriate erythropoietin elaboration. Ann N Y Acad Sci 149(1 Erythopoietin):528–538. [PubMed]
29. Shemisa K, Jafferjee N, Thomas D, Jacobs G, Meyerson HJ. 2014. Mycobacterium avium complex infection in a patient with sickle cell disease and severe iron overload. Case Rep Infect Dis 2014:405323. [PubMed]
30. Harisankar C, Mittal BR, Bhattacharya A, Singh B. 2010. FDG-PET/CT in diagnosis and early response evaluation of extra-pulmonary tuberculosis in a patient with aplastic anemia. J Postgrad Med 56:219–221. [PubMed]
31. González-Cortés C, Reyes-Ruvalcaba D, Diez-Tascón C, Rivero-Lezcano OM. 2009. Apoptosis and oxidative burst in neutrophils infected with Mycobacterium spp. Immunol Lett 126:16–21. [PubMed]
32. Eum SY, Kong JH, Hong MS, Lee YJ, Kim JH, Hwang SH, Cho SN, Via LE, Barry CE, III. 2010. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 137:122–128. [PubMed]
33. Appelberg R, Silva MT. 1989. T cell-dependent chronic neutrophilia during mycobacterial infections. Clin Exp Immunol 78:478–483. [PubMed]
34. Twomey JJ, Leavell BS. 1965. Leukemoid reactions to tuberculosis. Arch Intern Med 116:21–28. [PubMed]
35. Cicchitto G, Parravicini M, De Lorenzo S, Di Pisa G, Malacrida A. 1999. Tuberculosis and Pelger-Huët anomaly. Case report. Panminerva Med 41:367–369. [PubMed]
36. Savage PJ, Dellinger RP, Barnes JV, Carruth CW. 1984. Pelger-Huet anomaly of granulocytes in a patient with tuberculosis. Chest 85:131–132. [PubMed]
37. Lin FS, Wu MY, Tu WJ, Pan HQ, Zheng J, Shi JW, Fei ZT, Zhang RM, Yan WG, Shang MQ, Zheng Q, Wang MJ, Zhang X. 2015. A cross-sectional and follow-up study of leukopenia in tuberculosis patients: prevalence, risk factors and impact of anti-tuberculosis treatment. J Thorac Dis 7:2234–2242. [PubMed]
38. Juhlin L. 1963. Basophil and eosinophil leukocytes in various internal disorders. Acta Med Scand 174:249–254. [PubMed]
39. Kelsey PR. 1990. Blood film and marrow, p 3. In Delamore IW, Liu Yin JA (ed), Haematologic Aspects of Systemic Disease. Bailliere Tindall, London, England.
40. Vergne I, Chua J, Deretic V. 2003. Mycobacterium tuberculosis phagosome maturation arrest: selective targeting of PI3P-dependent membrane trafficking. Traffic 4:600–606. [PubMed]
41. Tan BH, Meinken C, Bastian M, Bruns H, Legaspi A, Ochoa MT, Krutzik SR, Bloom BR, Ganz T, Modlin RL, Stenger S. 2006. Macrophages acquire neutrophil granules for antimicrobial activity against intracellular pathogens. J Immunol 177:1864–1871. [PubMed]
42. Rathnayake PV, Kularathne WK, De Silva GC, Athauda BM, Nanayakkara SN, Siribaddana A, Baminiwatte D. 2015. Disseminated tuberculosis presenting as hemophagocytic lymphohistiocytosis in an immunocompetent adult patient: a case report. J Med Case Rep 9:294. [PubMed]
43. Brastianos PK, Swanson JW, Torbenson M, Sperati J, Karakousis PC. 2006. Tuberculosis-associated haemophagocytic syndrome. Lancet Infect Dis 6:447–454.
44. Chandra P, Chaudhery SA, Rosner F, Kagen M. 1975. Transient histiocytosis with striking phagocytosis of platelets, leukocytes, and erythrocytes. Arch Intern Med 135:989–991. [PubMed]
45. Mariani F, Goletti D, Ciaramella A, Martino A, Colizzi V, Fraziano M. 2001. Macrophage response to Mycobacterium tuberculosis during HIV infection: relationships between macrophage activation and apoptosis. Curr Mol Med 1:209–216. [PubMed]
46. Vijayan VK, Reetha AM, Jawahar MS, Sankaran K, Prabhakar R. 1992. Pulmonary eosinophilia in pulmonary tuberculosis. Chest 101:1708–1709. [PubMed]
47. Muzaffar TM, Shaifuzain AR, Imran Y, Haslina MN. 2008. Hematological changes in tuberculous spondylitis patients at the Hospital Universiti Sains Malaysia. Southeast Asian J Trop Med Public Health 39:686–689. [PubMed]
48. Renshaw AA, Gould EW. 2013. Thrombocytosis is associated with Mycobacterium tuberculosis infection and positive acid-fast stains in granulomas. Am J Clin Pathol 139:584–586. [PubMed]
49. Jurak SS, Aster R, Sawaf H. 1983. Immune thrombocytopenia associated with tuberculosis. Clin Pediatr (Philadelphia) 22:318–319.
50. al-Majed SA, al-Momen AK, al-Kassimi FA, al-Zeer A, Kambal AM, Baaqil H. 1995. Tuberculosis presenting as immune thrombocytopenic purpura. Acta Haematol 94:135–138. [PubMed]
51. Richards EM, Shneerson JM, Baglin TP. 1994. Thrombocytopenia responding to empirical antituberculous therapy. Clin Lab Haematol 16:89–90. [PubMed]
52. Kaufmann SH. 1991. The macrophage in tuberculosis: sinner or saint? The T cell decides. Pathobiology 59:153–155. [PubMed]
53. Boots RJ, Roberts AW, McEvoy D. 1992. Immune thrombocytopenia complicating pulmonary tuberculosis: case report and investigation of mechanisms. Thorax 47:396–397. [PubMed]
54. Pavithran K, Vijayalekshmi N. 1993. Thrombocytopenic purpura with tuberculous adenitis. Indian J Med Sci 47:239–240. [PubMed]
55. Finch SC, Castleman B. 1963. Case records of the Massachusetts General Hospital. N Engl J Med 238:378.
56. Tabarsi P, Merza MA, Marjani M. 2010. Active pulmonary tuberculosis manifesting with idiopathic thrombocytopenic purpura: a rare presentation. Braz J Infect Dis 14:639–640.
57. Ersley AJ. 1990. Hypersplenism and hyposplenism, p 695. In Williams WJ, Beutler E, Erslev AJ, Lichtman MA (ed), Hematology, 4th ed. McGraw-Hill, New York, NY.
58. Rosenberg MJ, Rumans LW. 1978. Survival of a patient with pancytopenia and disseminated coagulation associated with miliary tuberculosis. Chest 73:536–539.
59. Chia YC, Machin SJ. 1979. Tuberculosis and severe thrombocytopaenia. Br J Clin Pract 33:55–56, 58. [PubMed]
60. Marchasin S, Wallerstein RO, Aggeler PM. 1964. Variations of the platelet count in disease. Calif Med 101:95–100. [PubMed]
61. Tozkoparan E, Deniz O, Ucar E, Bilgic H, Ekiz K. 2007. Changes in platelet count and indices in pulmonary tuberculosis. Clin Chem Lab Med 45:1009–1013. [PubMed]
62. Tarhan G, Gümüşlü F, Yilmaz N, Saka D, Ceyhan I, Cesur S. 2006. Serum adenosine deaminase enzyme and plasma platelet factor 4 activities in active pulmonary tuberculosis, HIV-seropositive subjects and cancer patients. J Infect 52:264–268. [PubMed]
63. Feng Y, Dorhoi A, Mollenkopf H-J, Yin H, Dong Z, Mao L, Zhou J, Bi A, Weber S, Maertzdorf J, Chen G, Chen Y, Kaufmann SHE. 2014. Platelets direct monocyte differentiation into epithelioid-like multinucleated giant foam cells with suppressive capacity upon mycobacterial stimulation. J Infect Dis 210:1700–1710. [PubMed]
64. Hasanzad M. 2014. Bernard-Soulier syndrome (BSS) & tuberculosis: a case report. Int J Mycobacteriol 3:283–285. [PubMed]
65. Fantin B, Joly V, Elbim C, Golmard JL, Gougerot-Pocidalo MA, Yeni P, Carbon C. 1996. Lymphocyte subset counts during the course of community-acquired pneumonia: evolution according to age, human immunodeficiency virus status, and etiologic microorganisms. Clin Infect Dis 22:1096–1098. [PubMed]
66. Zaharatos GJ, Behr MA, Libman MD. 2001. Profound T-lymphocytopenia and cryptococcemia in a human immunodeficiency virus-seronegative patient with disseminated tuberculosis. Clin Infect Dis 33:E125–E128. [PubMed]
67. Yin Y, Qin J, Dai Y, Zeng F, Pei H, Wang J. 2015. The CD4+/CD8+ ratio in pulmonary tuberculosis: systematic and meta-analysis article. Iran J Public Health 44:185–193. [PubMed]
68. Laurence J. 1993. T-cell subsets in health, infectious disease, and idiopathic CD4+ T lymphocytopenia. Ann Intern Med 119:55–62. [PubMed]
69. Law K, Weiden M, Harkin T, Tchou-Wong K, Chi C, Rom WN. 1996. Increased release of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha by bronchoalveolar cells lavaged from involved sites in pulmonary tuberculosis. Am J Respir Crit Care Med 153:799–804. [PubMed]
70. Deveci F, Akbulut HH, Celik I, Muz MH, Ilhan F. 2006. Lymphocyte subpopulations in pulmonary tuberculosis patients. Mediators Inflamm 2006:89070. [PubMed]
71. Quaye IK. 2008. Haptoglobin, inflammation and disease. Trans R Soc Trop Med Hyg 102:735–742. [PubMed]
72. Williams WJ. 1990. Lymph node enlargement, p 950–955. In Williams WJ, Beutler E, Erslev AJ, Lichtman MA (ed), Hematology, 4th ed. McGraw-Hill, New York, NY. [PubMed]
73. Tereul JL, Matesanz R, Mampaso F, Lamas S, Herrero JA, Ortuno J. 1987. Pulmonary tuberculosis, cryoglobulinemia and immune complex glomerulonephritis. Clin Nephrol 27:48–49.
74. Kyle RA. 1982. Monoclonal gammopathy of undetermined significance (MGUS): a review. Clin Haematol 11:123–150. [PubMed]
75. Barry S, Breen R, Lipman M, Johnson M, Janossy G. 2009. Impaired antigen-specific CD4(+) T lymphocyte responses in cavitary tuberculosis. Tuberculosis (Edinburgh) 89:48–53. [PubMed]
76. Robson SC, White NW, Aronson I, Woollgar R, Goodman H, Jacobs P. 1996. Acute-phase response and the hypercoagulable state in pulmonary tuberculosis. Br J Haematol 93:943–949. [PubMed]
77. Selvaraj P, Venkataprasad N, Vijayan VK, Prabhakar R, Narayanan PR. 1994. Procoagulant activity of bronchoalveolar lavage fluids taken from the site of tuberculous lesions. Eur Respir J 7:1227–1232. [PubMed]
78. Casanova-Roman MM, Rios J, Sánchez-Porto A, Casanova-Bellido M. 2002. Deep venous thrombosis associated with pulmonary tuberculosis and transient protein S deficiency. Scand J Infect Dis 34:393–394. [PubMed]
79. Turken O, Kunter E, Sezer M, Solmazgul E, Cerrahoglu K, Bozkanat E, Ozturk A, Ilvan A. 2002. Hemostatic changes in active pulmonary tuberculosis. Int J Tuberc Lung Dis 6:927–932. [PubMed]
80. Gupta R, Brueton M, Fell J, Lyall H. 2003. An Afghan child with deep vein thrombosis. J R Soc Med 96:289–291. [PubMed]
81. Naithani R, Agrawal N, Choudhary VP. 2007. Deep venous thrombosis associated with tuberculosis. Blood Coagul Fibrinolysis 18:377–380. [PubMed]
82. Suárez Ortega S, Artiles Vizcaíno J, Balda Aguirre I, Melado Sánchez P, Arkuch Saade ME, Ayala Galán E, Betancor León P. 1993. Tuberculosis as risk factor for venous thrombosis. An Med Interna 10:398–400. (In Spanish.) [PubMed]
83. Raj M, Agrawal A. 2006. Inferior vena cava thrombosis complicating tuberculosis. N Z Med J 119:U2279. [PubMed]
84. Aliaga JL, de Gracia J, Vidal R, Pico M, Flores P, Sampol G. 1990. Acquired factor V deficiency in a patient with pulmonary tuberculosis. Eur Respir J 3:109–110. [PubMed]
85. Ogata H, Sakai S, Koiwa F, Tayama H, Kinugasa E, Ideura T, Akizawa T. 1999. Plasma exchange for acquired hemophilia: a case report. Ther Apher 3:320–322. [PubMed]
86. Balsarkar D, Joshi M. 2009. Ileal tuberculosis presenting as a case of massive rectal bleeding. Case report. BHJ 51:72–74.
87. Mengistu Z, Engh V, Melby KK, von der Lippe E, Qvigstad E. 2007. Postmenopausal vaginal bleeding caused by endometrial tuberculosis. Acta Obstet Gynecol Scand 86:631–632. [PubMed]
88. Nicolini A, Perazzo A, Gatto P, Piroddi IM, Barlascini C, Karamichali S, Strada P. 2016. A rare adverse reaction to ethambutol: drug-induced haemolytic anaemia. Int J Tuberc Lung Dis 20:704–705. [PubMed]
89. Claiborne RA, Dutt AK. 1985. Isoniazid-induced pure red cell aplasia. Am Rev Respir Dis 131:947–949. [PubMed]
90. Sharp RA, Lowe JG, Johnston RN. 1990. Anti-tuberculous drugs and sideroblastic anaemia. Br J Clin Pract 44:706–707. [PubMed]
91. Siddiqui MA, Khan IA. 2002. Isoniazid-induced lupus erythematosus presenting with cardiac tamponade. Am J Ther 9:163–165. [PubMed]
92. Aquinas M, Allan WG, Horsfall PA, Jenkins PK, Hung-Yan W, Girling D, Tall R, Fox W. 1972. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. BMJ 1:765–771. [PubMed]
93. Pereira J, Hidalgo P, Ocqueteau M, Blacutt M, Marchesse M, Nien Y, Letelier L, Mezzano D. 2000. Glycoprotein Ib/IX complex is the target in rifampicin-induced immune thrombocytopenia. Br J Haematol 110:907–910. [PubMed]
94. Prasad R, Kant S, Pandey DK. 1999. Rifampicin induced thrombocytopenia. J Assoc Physicians India 47:252. [PubMed]
95. Lee CH, Lee CJ. 1989. Thrombocytopenia—a rare but potentially serious side effect of initial daily and interrupted use of rifampicin. Chest 96:202–203. [PubMed]
96. Fahal IH, Williams PS, Clark RE, Bell GM. 1992. Thrombotic thrombocytopenic purpura due to rifampicin. BMJ 304:882. [PubMed]
97. Cameron SJ. 1974. Tuberculosis and the blood—a special relationship? Tubercle 55:55–72. [PubMed]
98. Passeron T, Ndir MC, Aubron C, Hovette P. 2004. Drug rash with eosinophilia and systemic symptoms (DRESS) due to streptomycin. Acta Derm Venereol 84:92–93. [PubMed]
99. Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S. 2010. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 50:49–55. [PubMed]
100. Colomba C, Rubino R, Siracusa L, Lalicata F, Trizzino M, Titone L, Tolomeo M. 2012. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes 5:552. [PubMed]
101. Insanov AB, Abdullaev FM, Kotsobashvili LI, Umniashkin AA. 1993. Gene geography of hereditary glucose-6-phosphate dehydrogenase deficiency and pulmonary tuberculosis in Azerbaijan. Probl Tuberk 2:5–8. (In Russian) [PubMed]
102. Chen CY, Sheng WH, Lai CC, Liao CH, Huang YT, Tsay W, Huang SY, Tang JL, Tien HF, Hsueh PR. 2012. Mycobacterial infections in adult patients with hematological malignancy. Eur J Clin Microbiol Infect Dis 31:1059–1066. [PubMed]
103. Anibarro L, Pena A. 2014. Tuberculosis in patients with haematological malignancies. Mediterr J Hematol Infect Dis 6:e2014026. [PubMed]
104. Lionnet F, Bachmeyer C, Sloma I, Rossier A, Thioliere B, Maier M, Grateau G, Girot R, Cadranel J. 2007. Tuberculosis in adult patients with sickle cell disease. J Infect 55:439–444. [PubMed]
microbiolspec.TNMI7-0004-2016.citations
cm/4/6
content/journal/microbiolspec/10.1128/microbiolspec.TNMI7-0004-2016
Loading

Citations loading...

Loading

Article metrics loading...

/content/journal/microbiolspec/10.1128/microbiolspec.TNMI7-0004-2016
2016-12-23
2017-11-22

Abstract:

Tuberculosis (TB) affects the production and life span of all hematologic cellular components. In addition, plasma coagulation factors may be affected, resulting in sometimes life-threatening complications. Iron, folate, and vitamin B metabolism is derailed. The pharmacological agents used for TB therapy may also cause hematologic changes. There are some uncommon manifestations of TB in nontuberculous hematologic patients. There have been some exciting developments in the field of imaging to screen for TB, TB pathophysiology at the cellular level, and our understanding of immune response in TB. Advances have been made in pharmacologic therapeutic options, including discovery of new drugs in the fight against drug-resistant TB, bearing in mind their hematologic effects. This chapter reviews and updates known hematologic effects of TB and its therapy and some lesser known effects of TB in patients with nontuberculous hematologic conditions.

Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Tables

Generic image for table
TABLE 1

Hematologic changes in TB

Source: microbiolspec December 2016 vol. 4 no. 6 doi:10.1128/microbiolspec.TNMI7-0004-2016
Generic image for table
TABLE 2

Hematologic toxicity from anti-TB therapy

Source: microbiolspec December 2016 vol. 4 no. 6 doi:10.1128/microbiolspec.TNMI7-0004-2016

Supplemental Material

No supplementary material available for this content.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error